Calidi Biotherapeutics Selects IL15 Superagonist for Antitumor Virotherapy Platform
Calidi Biotherapeutics announces selection of IL15 superagonist for antitumor virotherapy platform, showcasing innovative cancer treatment approach with potential for enhanced immune response and tumor elimination.
This news highlights a groundbreaking approach in cancer treatment with the potential to significantly enhance immune response and eliminate tumors while minimizing side effects. It showcases the innovative technology developed by Calidi Biotherapeutics in the fight against metastatic cancers, offering hope for improved efficacy and patient safety in cancer therapy.
